Xenetic Biosciences, Inc.
For the period ended Dec 31, 2024. Filed Mar 18, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 18, 2025
XBIO$1.80-3.9%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Financial Statements and Supplementary Data
ITEM 8 – FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
| Report of Independent Registered Public Accounting Firm (PCAOB ID 688) | F-1 |
|---|---|
| Consolidated Balance Sheets as of December 31, 2024 and 2023 | F-2 |
| Consolidated Statements of Operations for the years ended December 31, 2024 and 2023 | F-3 |
| Consolidated Statements of Stockholders’ Equity for the years ended December 31, 2024 and 2023 | F-4 |
| Consolidated Statements of Cash Flows for the years ended December 31, 2024 and 2023 | F-5 |
| Notes to Consolidated Financial Statements | F-6 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.